196 related articles for article (PubMed ID: 20630766)
1. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.
Cinelli MA; Cordero B; Dexheimer TS; Pommier Y; Cushman M
Bioorg Med Chem; 2009 Oct; 17(20):7145-55. PubMed ID: 19783447
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.
Cinelli MA; Morrell A; Dexheimer TS; Scher ES; Pommier Y; Cushman M
J Med Chem; 2008 Aug; 51(15):4609-19. PubMed ID: 18630891
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
[TBL] [Abstract][Full Text] [Related]
6. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Pommier Y; Cushman M
Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
Conda-Sheridan M; Reddy PV; Morrell A; Cobb BT; Marchand C; Agama K; Chergui A; Renaud A; Stephen AG; Bindu LK; Pommier Y; Cushman M
J Med Chem; 2013 Jan; 56(1):182-200. PubMed ID: 23259865
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
Nagarajan M; Morrell A; Antony S; Kohlhagen G; Agama K; Pommier Y; Ragazzon PA; Garbett NC; Chaires JB; Hollingshead M; Cushman M
J Med Chem; 2006 Aug; 49(17):5129-40. PubMed ID: 16913702
[TBL] [Abstract][Full Text] [Related]
10. 3-Arylisoquinolines as novel topoisomerase I inhibitors.
Khadka DB; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):724-34. PubMed ID: 21095131
[TBL] [Abstract][Full Text] [Related]
11. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.
Morrell A; Placzek M; Parmley S; Antony S; Dexheimer TS; Pommier Y; Cushman M
J Med Chem; 2007 Sep; 50(18):4419-30. PubMed ID: 17696418
[TBL] [Abstract][Full Text] [Related]
12. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2006 Dec; 49(26):7740-53. PubMed ID: 17181156
[TBL] [Abstract][Full Text] [Related]
13. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
15. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.
Morrell A; Placzek M; Parmley S; Grella B; Antony S; Pommier Y; Cushman M
J Med Chem; 2007 Sep; 50(18):4388-404. PubMed ID: 17676830
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of new 3-arylisoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity.
Cho WJ; Min SY; Le TN; Kim TS
Bioorg Med Chem Lett; 2003 Dec; 13(24):4451-4. PubMed ID: 14643344
[TBL] [Abstract][Full Text] [Related]
17. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
Strumberg D; Pommier Y; Paull K; Jayaraman M; Nagafuji P; Cushman M
J Med Chem; 1999 Feb; 42(3):446-57. PubMed ID: 9986716
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
Zhu L; Zhang X; Lei N; Liu W; Miao Z; Zhuang C; Sheng C; Guo W; Dong G; Yao J; Cheng P; Zhang W
Chem Biodivers; 2012 Jun; 9(6):1084-94. PubMed ID: 22700227
[TBL] [Abstract][Full Text] [Related]
20. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
